Effect of Capecitabine plus Oxaliplatin for Advanced Adenocarcinoma of Ampulla of Vater.
10.15279/kpba.2017.22.3.127
- Author:
Jung Hwan LEE
1
;
Kyung Hee KIM
;
Sang Myung WOO
;
Sang Jae PARK
;
Sung Sik HAN
;
Eun Kyung HONG
;
Young Hwan KOH
;
Ju Hee LEE
;
Woo Jin LEE
Author Information
1. Pancreatobiliary Cancer Clinic, National Cancer Center, Goyang, Korea. wsm@ncc.re.kr
- Publication Type:Original Article
- Keywords:
Adenocarcinoma;
Ampulla of Vater;
Capecitabine;
Oxaliplatin;
Antineoplastic agents
- MeSH:
Adenocarcinoma*;
Administration, Oral;
Ambulatory Care Facilities;
Ampulla of Vater*;
Antineoplastic Agents;
Capecitabine*;
Disease-Free Survival;
Drug Therapy;
Follow-Up Studies;
Humans;
Injections, Intravenous;
Mortality;
Nausea;
Rare Diseases;
Retrospective Studies;
Vomiting
- From:Korean Journal of Pancreas and Biliary Tract
2017;22(3):127-133
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIM: Adenocarcinoma arising from the ampulla of Vater is a rare disease and has limited data regarding outcome of palliative chemotherapy. We investigated the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with advanced ampullary adenocarcinoma. METHODS: From October 2006 to January 2014, we retrospectively analyzed 28 patients with advanced ampullary adenocarcinoma treated by XELOX regimen at single institution. All the patients had histologically confirmed stage IV or recurrent ampullary adenocarcinoma. XELOX was administered in outpatient clinic every 3 weeks according to the following protocol: oral administration of capecitabine 750 mg/m² twice a day on days 1-14 and intravenous injection of oxaliplatin 130 mg/m² on day 1. RESULTS: With follow-up of median 24.6 months (range 4.0–78.0 months), median progression-free survival (PFS) was 4.8 months (range 0.7–26.1 months), and median overall survival (OS) was 11.9 months (range 2.0–36.0 months). One patient (4%) achieved complete response and 5 patients (18%) showed partial response. There were no significant differences for PFS and OS according to response by chemotherapy. The most common grade 3 adverse events in patients were nausea and vomiting (10.7%). There was no treatment-related mortality. CONCLUSIONS: XELOX regimen is well tolerated and show moderate activity against advanced ampullary adenocarcinoma.
